Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

Background: Knowledge of factors able to predict the clinical outcome of homogenous series of entero-pancreatic endocrine tumours treated with somatostatin analogues is poor. This study was aimed at identifying predictors for efficacy of somatostatin analogues at inhibiting tumour growth and modifyi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2006-03, Vol.17 (3), p.461-466
Hauptverfasser:	Panzuto, F., Di Fonzo, M., Iannicelli, E., Sciuto, R., Maini, C. L., Capurso, G., Milione, M., Cattaruzza, M. S., Falconi, M., David, V., Ziparo, V., Pederzoli, P., Bordi, C., Fave, G. Delle
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences carcinoids Cell Differentiation Clinical outcomes Female Gastroenterology. Liver. Pancreas. Abdomen Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences metastases Middle Aged Neoplasm Metastasis neuroendocrine tumours pancreatic endocrine tumours Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Pharmacology. Drug treatments Somatostatin - adverse effects Somatostatin - analogs & derivatives Somatostatin - therapeutic use somatostatin analogues Survival Analysis treatment Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!